Skip to main content
. Author manuscript; available in PMC: 2009 Nov 25.
Published in final edited form as: Eur J Immunol. 1998 Oct;28(10):2991–3002. doi: 10.1002/(SICI)1521-4141(199810)28:10<2991::AID-IMMU2991>3.0.CO;2-B

Figure 2.

Figure 2

Agonist activity of p33 and its variants. (A) TCR transgenic P14 thymocytes were incubated with EL-4 cells as APC and graded concentrations of the indicated peptides for 18 h and then stained with anti-CD4 and anti-CD8. Deletion of immature CD4hiCD8hi DP thymocytes is given as % of control without peptide. (B) Graded concentrations of the indicated peptides were preincubated with 51Cr-labeled EL-4 cells for 30 min. P14.G5 CTL were then added and a standard 4-h Cr-release assay performed. The effector/target ratio was 5/1.